Patents by Inventor Seattle Genetics, Inc.

Seattle Genetics, Inc. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Variant Target Binding Agents and Uses Thereof
    Publication number: 20140105922
    Abstract: The present invention provides variant target binding agents and methods relating to the use of such binding agents for the prophylaxis or treatment of cancers and immunological disorders. The variant target binding agent is conjugated to a therapeutic agent that exerts a cytotoxic, cytostatic, or immunomodulatory effect on target cells.
    Type: Application
    Filed: March 14, 2013
    Publication date: April 17, 2014
    Applicant: SEATTLE GENETICS, INC.
    Inventor: SEATTLE GENETICS, INC.
  • Variant Target Binding Agents and Uses Thereof
    Publication number: 20140086942
    Abstract: The present invention provides variant target binding agents and methods relating to the use of such binding agents for the prophylaxis or treatment of cancers and immunological disorders. The variant target binding agent is conjugated to a therapeutic agent that exerts a cytotoxic, cytostatic, or immunomodulatory effect on target cells.
    Type: Application
    Filed: March 14, 2013
    Publication date: March 27, 2014
    Applicant: SEATTLE GENETICS, INC.
    Inventor: SEATTLE GENETICS, INC.
  • SELF-STABILIZING LINKER CONJUGATES
    Publication number: 20130309256
    Abstract: The present invention provides Ligand-Drug Conjugates, Drug-Linkers, Linkers, and Ligand-Linker Conjugates comprising a self-stabilizing linker assembly component.
    Type: Application
    Filed: March 13, 2013
    Publication date: November 21, 2013
    Inventor: Seattle Genetics, Inc.
  • ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 24P4C12 PROTEINS
    Publication number: 20130136756
    Abstract: Antibody drug conjugates (ADC's) that bind to 24P4C12 protein and variants thereof are described herein. 24P4C12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
    Type: Application
    Filed: November 8, 2012
    Publication date: May 30, 2013
    Applicants: SEATTLE GENETICS, INC., AGENSYS, INC.
    Inventors: Agensys, Inc., Seattle Genetics, Inc.
  • MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS
    Publication number: 20130123465
    Abstract: Auristatin peptide analogs of MeVal-Val-Dil-Dap-Phe (MMAF) are provided having C-terminal phenylalanine residue side chain replacements or modifications which are provided alone or attached to ligands through various linkers. The related conjugates can target specific cell types to provide therapeutic benefit.
    Type: Application
    Filed: November 1, 2012
    Publication date: May 16, 2013
    Applicant: Seattle Genetics, Inc.
    Inventor: Seattle Genetics, Inc.
  • New binder-drug conjugates (ADCs) and use thereof
    Publication number: 20130095123
    Abstract: The present application relates to new binder-drug conjugates (ADCs) of N,N-dialkylauristatins that are directed against the target C4.4a, to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for treating and/or preventing illnesses, and also to the use of these ADCs for producing medicaments for treating and/or preventing illnesses, more particularly hyperproliferative and/or angiogenic diseases such as, for example, cancer diseases. Such treatments may be practised as a monotherapy or else in combination with other medicaments or further therapeutic measures.
    Type: Application
    Filed: October 20, 2012
    Publication date: April 18, 2013
    Applicants: SEATTLE GENETICS, INC., BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Bayer Pharma AG, Bayer Intellectual Property GmbH, Seattle Genetics, Inc.
  • Nucleic Acids Encoding Humanized Anti-CD40 Antibodies
    Publication number: 20130023047
    Abstract: Provided are humanized anti-CD40 antibodies and antigen-binding fragments and methods for treating disease characterized by expression of CD40 antigen.
    Type: Application
    Filed: September 19, 2012
    Publication date: January 24, 2013
    Applicants: Genentech, Inc. A member of the Roche Group, SEATTLE GENETICS, INC.
    Inventors: Seattle Genetics, Inc., Genentech, Inc. A member of the Roche Group